These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35316701)

  • 21. Comparison of United States and International Ophthalmic Drug Pricing.
    Gong D; Chang JS; Barbany M; Corcostegui BF; Kağan Değirmenci MF; Ishikawa H; Mammo Z; Ozmert E; Rossi T; Chang S
    Ophthalmology; 2019 Oct; 126(10):1358-1365. PubMed ID: 31146962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Payer License Agreement, or "Netflix model," for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition.
    Matthews DW; Coleman S; Razavi H; Izaret JM
    Liver Int; 2022 Jul; 42(7):1503-1516. PubMed ID: 35289467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
    Robinson JC
    Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic Efficiency.
    Garrison LP; Jiao B; Dabbous O
    Value Health; 2023 Mar; 26(3):336-343. PubMed ID: 36336584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
    Persson U; Svensson J; Pettersson B
    Appl Health Econ Health Policy; 2012 Jul; 10(4):217-25. PubMed ID: 22676213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Private versus social incentives for pharmaceutical innovation.
    González P; Macho-Stadler I; Pérez-Castrillo D
    J Health Econ; 2016 Dec; 50():286-297. PubMed ID: 26944633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D.
    Schulthess D; Gassull D; Maisel S
    Ther Innov Regul Sci; 2019 Nov; 53(6):746-751. PubMed ID: 31771361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Funding pharmaceutical innovation through direct tax credits.
    Lybecker KM; Freeman RA
    Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea.
    Hasan SS; Kow CS; Dawoud D; Mohamed O; Baines D; Babar ZU
    Value Health Reg Issues; 2019 May; 18():18-23. PubMed ID: 30414506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing.
    Wilson L; Turkistani FA; Huang W; Tran DM; Lin TK
    PLoS One; 2018; 13(5):e0197449. PubMed ID: 29799850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
    Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
    Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing.
    Alkhatib NS; Ramos K; Erstad B; Slack M; McBride A; Bhattacharjee S; Abraham I
    J Med Econ; 2020 Nov; 23(11):1215-1222. PubMed ID: 32845794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fee-for-service payment is not the (main) problem.
    Dowd BE; Laugesen MJ
    Health Serv Res; 2020 Aug; 55(4):491-495. PubMed ID: 32700387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.